Mechanisms of disease and treatment in novel metabolic developmental brain disorders

新型代谢性发育性脑疾病的疾病机制和治疗

基本信息

  • 批准号:
    10712302
  • 负责人:
  • 金额:
    $ 31.42万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-12-01 至 2026-11-30
  • 项目状态:
    未结题

项目摘要

PROJECT SUMMARY The locus coeruleus (LC) is a vulnerable brain area implicated in neurodegenerative diseases such as AD/ADRD. LC has been documented as among the earliest brain regions to degenerate in AD/ADRD, and LC degeneration is correlated with disease pathogenesis in AD/ADRD. In our work from the Parent Award (R01NS121618), we show that the Gpt2-null mouse demonstrates the earliest known loss of LC neurons, by postnatal day 18, in any genetic mouse model yet studied. Prior studies have also demonstrated that LC degeneration occurs in several mouse models of AD/ADRD, although this degeneration occurs later in the life of the animal, such as at 6 months of age. The underlying mechanisms of LC neuronal vulnerability in AD/ADRD are unknown; therefore, there is a critical opportunity for progress through the investigation of Gpt2- mediated mechanisms in LC vulnerability in AD/ADRD. The overriding objectives of this Supplement Application, which are strongly in line with the Parent Award, are: 1) to begin to define Gpt2-mediated mitochondrial mechanisms of LC vulnerability; and 2) to determine the extent to which these Gpt2-mediated mechanisms underlie LC vulnerability in AD/ADRD genetic models. Elucidation of Gpt2-mediated mechanisms in LC neuron death, and in AD/ADRD, will serve as a foundation for novel paths to treatment in AD/ADRD, including potentially metabolite supplements being tested in the Parent Application. The research in the Supplement Application will also permit the formation of a collaborative team to investigate mechanisms of LC vulnerability in AD/ADRD and the collection of preliminary data for follow-up AD/ADRD grant applications. The finding of prominent and early LC neurodegeneration in the Gpt2-null mouse represents an important opportunity to advance LC research relevant to AD/ADRD. In summary, this new line of AD/ADRD research will have a sustained impact on the AD/ADRD field as the research addresses the clinically relevant topic of LC neurodegeneration in AD/ADRD and promises to build a path to new metabolic treatments.
项目摘要 蓝斑(LC)是一个脆弱的大脑区域,与神经退行性疾病有关, AD/ADRD。LC已被证明是AD/ADRD中最早退化的脑区之一,并且LC 变性与AD/ADRD中的疾病发病机制相关。在我们的工作从家长奖 (R 01 NS 121618),我们通过以下方式显示Gpt 2-null小鼠证明了已知最早的LC神经元损失: 出生后第18天,在任何遗传小鼠模型尚未研究。先前的研究也表明,LC 在AD/ADRD的几种小鼠模型中发生变性,尽管这种变性发生在生命后期 例如在6个月大时。LC神经元易损性的潜在机制 AD/ADRD未知;因此,通过研究Gpt 2- AD/ADRD中LC脆弱性的介导机制。本补编的首要目标 申请,这是强烈符合家长奖,是:1)开始定义Gpt 2介导的 LC脆弱性的线粒体机制;和2)确定这些Gpt 2介导的 机制是AD/ADRD遗传模型中LC脆弱性的基础Gpt 2介导机制的阐明 在LC神经元死亡和AD/ADRD中,将作为AD/ADRD治疗的新途径的基础, 包括在母申请中测试的潜在代谢物补充剂。之研究 补充申请还将允许成立一个合作小组,以调查LC的机制 AD/ADRD的脆弱性和收集后续AD/ADRD赠款申请的初步数据。的 在Gpt 2基因敲除小鼠中发现的突出和早期LC神经变性代表了一个重要的 有机会推进与AD/ADRD相关的LC研究。总之,这条新的AD/ADRD研究路线 将对AD/ADRD领域产生持续影响,因为研究涉及LC的临床相关主题 AD/ADRD中的神经变性,并有望建立新的代谢治疗方法。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Eric M Morrow其他文献

Postictal psychosis: presymptomatic risk factors and the need for further investigation of genetics and pharmacotherapy
  • DOI:
    10.1186/1744-859x-5-9
  • 发表时间:
    2006-07-21
  • 期刊:
  • 影响因子:
    3.100
  • 作者:
    Eric M Morrow;Jennifer M Lafayette;Edward B Bromfield;Gregory Fricchione
  • 通讯作者:
    Gregory Fricchione

Eric M Morrow的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Eric M Morrow', 18)}}的其他基金

Mechanisms of Disease and Treatments in Novel Metabolic Development Brain Disorders
新型代谢发育脑疾病的疾病机制和治疗
  • 批准号:
    10622084
  • 财政年份:
    2022
  • 资助金额:
    $ 31.42万
  • 项目类别:
Mechanisms of disease and treatment in novel metabolic developmental brain disorders
新型代谢性发育性脑疾病的疾病机制和治疗
  • 批准号:
    10375639
  • 财政年份:
    2021
  • 资助金额:
    $ 31.42万
  • 项目类别:
Mechanisms of Disease and Treatment in Novel Metabolic Developmental Brain Disorders
新型代谢性发育性脑疾病的疾病机制和治疗
  • 批准号:
    10527375
  • 财政年份:
    2021
  • 资助金额:
    $ 31.42万
  • 项目类别:
Mechanisms of Disease and Treatment in Novel Metabolic Developmental Brain Disorders
新型代谢性发育性脑疾病的疾病机制和治疗
  • 批准号:
    10745757
  • 财政年份:
    2021
  • 资助金额:
    $ 31.42万
  • 项目类别:
Neurodegenerative mechanisms in Christianson syndrome and NHE6-related disorders
Christianson 综合征和 NHE6 相关疾病的神经退行性机制
  • 批准号:
    9811045
  • 财政年份:
    2019
  • 资助金额:
    $ 31.42万
  • 项目类别:
Neurodegenerative Mechanisms in Christianson Syndrome and NHE6-Related Disorders
Christianson 综合征和 NHE6 相关疾病的神经退行性机制
  • 批准号:
    10417212
  • 财政年份:
    2019
  • 资助金额:
    $ 31.42万
  • 项目类别:
Neurodegenerative mechanisms in Christianson syndrome and NHE6-related disorders
Christianson 综合征和 NHE6 相关疾病的神经退行性机制
  • 批准号:
    10020810
  • 财政年份:
    2019
  • 资助金额:
    $ 31.42万
  • 项目类别:
Neurodegenerative Mechanisms in Christianson Syndrome and NHE6-Related Disorders
Christianson 综合征和 NHE6 相关疾病的神经退行性机制
  • 批准号:
    10653694
  • 财政年份:
    2019
  • 资助金额:
    $ 31.42万
  • 项目类别:
Neurodegenerative Mechanisms in Christianson Syndrome and NHE6-Related Disorders
Christianson 综合征和 NHE6 相关疾病的神经退行性机制
  • 批准号:
    10213154
  • 财政年份:
    2019
  • 资助金额:
    $ 31.42万
  • 项目类别:
Neurodegenerative mechanisms in Christianson syndrome and NHE6-related disorders
Christianson 综合征和 NHE6 相关疾病的神经退行性机制
  • 批准号:
    10164658
  • 财政年份:
    2019
  • 资助金额:
    $ 31.42万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 31.42万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 31.42万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 31.42万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 31.42万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 31.42万
  • 项目类别:
    Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 31.42万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 31.42万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 31.42万
  • 项目类别:
    EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 31.42万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 31.42万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了